help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 2, 142-150, February 2007; doi:10.1634/theoncologist.12-2-142
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 BRCA1, a Potential Predictive Biomarker in the Treatment of Breast C...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by James, C. R.
Right arrow Articles by Harkin, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by James, C. R.
Right arrow Articles by Harkin, D. P.

Breast Cancer

BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer

Colin R. James, Jennifer E. Quinn, Paul B. Mullan, Patrick G. Johnston, D. Paul Harkin

Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom

Key Words. BRCA1 • Breast cancer • Chemotherapy • Prognosis • Predictive marker • Sensitivity • Resistance

Correspondence: Professor D. Paul Harkin, Ph.D., Centre for Cancer Research and Cell Biology, Queen’s University Belfast, University Floor, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland, U.K. Telephone: (+44)289032 9241; Fax: (+44)289026 3744; e-mail: d.harkin{at}qub.ac.uk

To date, estrogen receptor, progestogen receptor, and HER2/neu represent molecular biomarkers currently used in routine clinical practice to aid treatment decisions. Over the last few years, a large body of preclinical and retrospective clinical data has accumulated that suggests that BRCA1 mutation functions as a novel predictive marker of response to chemotherapy. This article reviews the role of BRCA1 as a predictive marker of chemotherapy response in breast cancer and examines the link between BRCA1 deficiency and the basal-like phenotype.

Search strategy. Data for this article were identified through MEDLINE and PubMed searches for published reports using the terms BRCA1, breast cancer, basal-like, chemotherapy, prognosis, and predictive markers. In some cases, due to the restriction of space, readers are referred to review articles to allow further reading. Only articles published in English were included.




This article has been cited by other articles:


Home page
 JCOHome page
E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis
Basal-Like Breast Cancer: A Critical Review
J. Clin. Oncol., May 20, 2008; 26(15): 2568 - 2581.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Quinn, C. R. James, G. E. Stewart, J. M. Mulligan, P. White, G. K.F. Chang, P. B. Mullan, P. G. Johnston, R. H. Wilson, and D. P. Harkin
BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy
Clin. Cancer Res., December 15, 2007; 13(24): 7413 - 7420.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Ann. Onc., July 1, 2007; 18(7): 1133 - 1144.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2007 by AlphaMed Press.